Incentive Plan - The company granted a total of 494,595 restricted stock units under the incentive plan on December 5, 2024, with the closing price of H-shares at HKD 29.05 per share on the grant date [3]. - The number of restricted stock units granted during the reporting period represents approximately 0.82% of the weighted average number of shares issued during the reporting period, excluding treasury shares [3]. - The purchase price for the restricted stock units must generally be paid by the grantees within one month after the grant date [3].

Director Remuneration - The total remuneration for the nine directors in the fiscal year 2024 amounted to RMB 35,230,000, with the highest paid being Dr. Liang Nianjian at RMB 21,513,000[3]. - In the fiscal year 2023, the total remuneration for the nine directors was RMB 152,088,000, with Dr. Liang Nianjian receiving RMB 135,731,000, marking a significant increase from the previous year[4]. - For the fiscal year 2022, the total remuneration for the ten directors was RMB 33,319,000, with Dr. Liang Nianjian earning RMB 21,917,000, indicating a growth trend in director compensation over the years[5]. - The remuneration structure includes salary, retirement benefits, and other welfare payments, demonstrating a comprehensive approach to director compensation[3][4][5]. - The company has shown a trend of increasing director remuneration over the years, with a notable rise in the total compensation from RMB 33,319,000 in 2022 to RMB 152,088,000 in 2023[5][4]. Governance Structure - The company has maintained a consistent number of directors, with nine directors in fiscal year 2024 and eight in fiscal year 2023, reflecting stability in governance[3][4]. - The board of directors includes five executive directors, one non-executive director, and three independent non-executive directors, ensuring a diverse governance structure[7]. Financial Reporting - The financial reports for the fiscal years 2022, 2023, and 2024 have been rounded to the nearest million and thousand RMB, ensuring clarity in financial disclosures[2]. - The company’s auditor has acknowledged the changes in the remuneration details without affecting other information in the annual reports, indicating compliance with regulatory standards[6]. - The financial disclosures are consistent across the annual reports, with no significant changes apart from the remuneration details, ensuring transparency for stakeholders[6].

ITE (HOLDINGS) LIMITED （於開曼群島註冊成立的有限公司） （股份代號: 8092） 中期業績公佈 截至二零二五年九月三十日止六個月 香港聯合交易所有限公司（「聯交所」）GEM 的特色 GEM 的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在主板上市公司帶有較高投 資風險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決 定。 由於 GEM 上市公司普遍為中小型公司，在 GEM 買賣的證券可能會較於主板買賣的證券承受較大的市 場波動風險，同時無法保證在 GEM 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公佈的內容概不負責，對其準確性或完整性亦不發表任何聲 明，並明確表示概不會就本公佈全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 本公佈的資料乃遵照聯交所《 GEM 證券上市規則》（「 GEM 上市規則」）而刊載，旨在提供有關 ITE (Holdings) Limited（「本公司」）的資料；本公司各董事（「董事」）願就本公佈共同及個別承擔全部責任。各董事在 作出一切合理查詢後，確認就所知及所 ...

Financial Performance - Total revenue for Q3 2025 increased by 14% year-over-year, reaching $116.1 million[6] - Operating loss for Q3 2025 was $48.8 million, a reduction of 28% compared to the previous year[6] - Adjusted operating loss narrowed by 42% to $28 million for Q3 2025[6] - In Q3 2025, product revenue net amounted to $115.4 million, a 13% increase year-over-year, driven by sales growth of Newzai and Dingyoule[11] - The net loss for Q3 2025 was $36 million, with a loss per share of $0.03, an improvement from a net loss of $41.7 million and a loss per share of $0.04 in the same period of 2024[11] - Total revenue for the three months ended September 30, 2025, was $116,095,000, representing a 13% increase compared to $102,265,000 in the same period of 2024[36] - Product revenue for the nine months ended September 30, 2025, reached $330,095,000, a 14% increase from $289,102,000 in the same period of 2024[38] - Operating loss for the three months ended September 30, 2025, was $(48,822,000), a 28% improvement compared to $(67,853,000) in the same period of 2024[39] - Net loss for the nine months ended September 30, 2025, was $(125,128,000), down from $(175,419,000) in the same period of 2024[37] - Adjusted operating loss for the three months ended September 30, 2025, was $(27,998,000), compared to $(48,187,000) in the same period of 2024[39] Guidance and Projections - The company has set a full-year revenue guidance of at least $460 million for 2025[6] - The company adjusted its full-year 2025 total revenue guidance to at least $460 million[22] - Future projections include expectations for revenue growth, profitability, and cash flow from commercialized products and clinical-stage candidates[31] Research and Development - Zocilurtatug Pelitecan (zoci) has shown a 68% overall response rate in the 1.6 mg/kg dose group for the treatment of extensive-stage small cell lung cancer[9] - The median duration of response (DoR) for patients in the same group is estimated at 6.1 months[9] - KarXT has been included in national treatment guidelines in China, highlighting the urgent need for new therapies in the schizophrenia field[6] - The company plans to submit a marketing authorization application for tumor treating fields therapy for pancreatic cancer in Q4 2025[9] - ZL-1503 (IL-13xIL-31R) has initiated a global Phase 1/1b study to evaluate its safety and pharmacokinetics[9] - The company is preparing for the anticipated launch of KarXT in the schizophrenia market[6] - KarXT was included in the "China Schizophrenia Prevention and Treatment Guidelines (2025 Edition)" as the first national-level guideline globally, highlighting its effectiveness in three symptom areas[11] - The company plans to submit a new drug clinical trial application for ZL-6201 for treating sarcoma patients in Q4 2025[15] - The company expects to announce key results from ongoing clinical studies in 2026, including updates on the efficacy of Zocilurtatug Pelitecan in treating various cancers[17] - The company is preparing to submit marketing authorization applications for several products, including a new treatment for first-line pancreatic cancer in Q4 2025[18] Financial Position - As of September 30, 2025, cash and cash equivalents totaled $81.72 million, down from $83.23 million as of June 30, 2025[12] - As of September 30, 2025, cash and cash equivalents increased to $717.155 million from $449.667 million as of December 31, 2024, representing a growth of approximately 59.7%[34] - Total assets decreased to $1.159 billion as of September 30, 2025, from $1.186 billion as of December 31, 2024, a decline of about 2.3%[34] - Current liabilities increased to $359.769 million as of September 30, 2025, compared to $299.385 million as of December 31, 2024, reflecting an increase of approximately 20.2%[34] - The company reported a total of $85.377 million in accounts receivable as of September 30, 2025, slightly up from $85.178 million as of December 31, 2024[34] - Inventory net increased to $67.135 million as of September 30, 2025, from $39.875 million as of December 31, 2024, indicating a rise of approximately 68.5%[34] - The company has a non-current restricted cash of $1.115 million as of September 30, 2025, consistent with $1.114 million as of December 31, 2024[34] - Total liabilities rose to $398.995 million as of September 30, 2025, compared to $344.855 million as of December 31, 2024, marking an increase of about 15.7%[34] - The total equity as of September 30, 2025, was $759,945,000, a decrease from $840,898,000 as of December 31, 2024[35] - The total liabilities and equity as of September 30, 2025, was $1,158,940,000, compared to $1,185,753,000 as of December 31, 2024[35] - The company reported a foreign currency translation adjustment loss of $(6,703,000) for the three months ended September 30, 2025[37] Operational Focus - The company emphasizes the importance of non-GAAP financial metrics for understanding operational performance and financial results[30] - The company is focused on addressing unmet medical needs in oncology, immunology, neuroscience, and infectious diseases through innovative product development[27]

Financial Performance - For the six months ended September 30, 2025, the group's revenue was approximately HKD 81.06 million, an increase of 110.4% compared to approximately HKD 38.54 million for the same period last year[4] - The group's net profit for the reporting period was approximately HKD 35.66 million, a significant increase of 595.6% from approximately HKD 5.13 million in the same period last year[4] - The basic earnings per share attributable to the owners of the company was HKD 5.4 cents, compared to HKD 0.95 cents for the same period last year[4] - Total revenue for the reporting period was HKD 81,059,737, an increase of HKD 42,524,519 or 110.4% compared to the same period last year[39] - Net profit for the reporting period was HKD 35,659,399, an increase of HKD 30,533,249 or 595.6% compared to the same period last year[39] User Growth - As of September 30, 2025, the number of registered users reached approximately 869,920, an increase of 5.5% or 45,520 users from approximately 824,400 users a year ago[4] - As of September 30, 2025, the group had approximately 869,920 registered users, an increase of 45,520 users or 5.5% from 824,400 users a year earlier[42] Assets and Liabilities - Non-current assets increased to HKD 23,823,555, up from HKD 22,332,372, representing a growth of approximately 6.7%[7] - Current assets rose significantly to HKD 364,682,362, compared to HKD 200,604,128, marking an increase of about 81.7%[7] - Total liabilities increased to HKD 45,223,520, up from HKD 37,340,410, reflecting a growth of approximately 21.4%[7] - Net asset value reached HKD 341,745,777, compared to HKD 185,478,588, indicating a substantial increase of around 84.3%[7] - The group’s total liabilities, including trade and other payables, were HKD 32,886,000 as of September 30, 2025, compared to HKD 27,879,000 as of March 31, 2025[30] Cash Flow and Investments - The company reported a profit of HKD 33,691,466 for the six months ended September 30, 2025, compared to a loss in the previous period[8] - The company reported a net cash outflow from investing activities of HKD 66,937,724, primarily due to payments for intangible assets amounting to HKD 5,425,303[9] - Cash and cash equivalents decreased by HKD 6,049,408 during the reporting period, with cash and cash equivalents at HKD 105,698,776 as of September 30, 2025[9] - The company’s cash and cash equivalents rose to HKD 222,842,583, up from HKD 162,521,973, representing a growth of about 37.1%[7] - The group’s cash and cash equivalents increased to HKD 222,843,000 as of September 30, 2025, compared to HKD 162,522,000 as of March 31, 2025[29] Revenue Breakdown - Revenue from integrated trading terminal products and system services was HKD 80,498, with significant contributions from financial services licensed under the Securities and Futures Ordinance, which generated HKD 44,343, up from HKD 8,597 in 2024[16] - Revenue from Hong Kong customers was HKD 68,138, significantly up from HKD 29,705 in the previous year, indicating a growth of approximately 129.1%[18] - Revenue from customers in China increased to HKD 12,922 from HKD 8,830, representing a growth of approximately 46.5%[18] - The company’s SaaS services revenue increased to HKD 20,414, up from HKD 13,471, marking a growth of approximately 51.5%[16] - Revenue from licensed financial services surged 415.8% to HKD 44,343,046, with underwriting and co-underwriting services revenue increasing 440.2% to HKD 38,831,633, representing 47.9% of total group revenue[43] Shareholder Information - The issued share capital as of September 30, 2025, was HKD 6,800,000, with a total of 680,000,000 ordinary shares issued[57] - Mr. Liu Yong holds a total of 226,001,789 shares, representing 33.24% of the company's equity[67] - Mr. Wan Yong also holds a total of 226,001,789 shares, representing 33.24% of the company's equity[67] - Major shareholders include Liu Xiaoming and Chen Chaoxia, each holding 226,001,789 shares, representing 33.24% of the total shares[70] Corporate Governance - The company confirmed compliance with the GEM listing rules regarding securities trading by directors during the reporting period[79] - The company adhered to all applicable corporate governance codes, with a noted deviation from the code regarding the separation of the roles of Chairman and CEO[80][81] - The Chairman and CEO roles are currently held by the same individual, which the board believes provides strong and consistent leadership[81] - The board will continue to review the corporate governance practices and consider separating the roles at an appropriate time[82] Future Plans - The company plans to enhance its SaaS platform and data service capabilities while actively developing licensed financial services, focusing on underwriting and innovative enterprises[59] - The group is preparing to advance its GEM to Main Board transfer plan, expected to initiate in the first half of 2026, to improve stock liquidity and company valuation[59] Miscellaneous - The board of directors does not recommend the payment of any dividend for the reporting period, consistent with the previous year[4] - No significant capital commitments were reported as of September 30, 2025[36] - No significant events occurred after September 30, 2025, that could materially impact the group's assets or future operations[37] - The audit committee has reviewed the unaudited consolidated financial statements for the six months ending September 30, 2025, and confirmed compliance with applicable accounting standards and GEM listing rules[90]

Credit Loss and Financial Performance - The expected credit loss for the independent after-sales company is approximately RMB 139.6 million, primarily due to the company's failure to pay interest on time [4]. - The net liabilities attributable to the independent after-sales company increased to approximately RMB 855 million as of December 31, 2024, with an operating loss of about RMB 36 million and financial costs of approximately RMB 32 million recorded for the year [4]. - The expected credit loss provision as of December 31, 2024, is RMB 712.4 million, after accounting for previous provisions [6]. - The total risk value faced by the company in the event of default by the independent after-sales company is the sum of the total advances and receivable interest [8]. - The default probability is set at 100%, consistent with the previous two years, while the default loss rate increased from 68.9% to 82.4% due to prolonged overdue periods [8]. - The expected credit loss provision is calculated using the formula: expected credit loss = default risk x default probability x default loss rate [8]. Repayment Efforts - The company received repayments totaling RMB 40 million from the independent after-sales company on October 9 and 10, 2025, and remains committed to recovering the outstanding balance [7]. - The company is in ongoing discussions with the independent after-sales company to explore feasible repayment solutions [4]. Operational Efficiency - The independent after-sales company is actively working to optimize operational efficiency, including restructuring staff and reducing operating costs [4]. - The total number of stock options available for grant under the stock option plan is 122,570,067 shares, representing 8.05% of the issued shares as of the report date [3].

Stock Options - Fenbi Ltd. reported a total of 5,020,000 unexercised stock options as of January 1, 2024, with 2,010,000 options exercised during the reporting period [8]. - The weighted average exercise price for the unexercised stock options is HKD 4.46 per share [8]. - The company has a total of 66,956,760 stock options granted from January 1, 2017, to October 25, 2022, with 37,120,790 options exercised and 29,417,810 remaining unexercised [8]. - The 2023 stock option plan allows for options to be exercised until the tenth anniversary of the grant date, subject to the terms of the plan [9]. Board of Directors - The company’s board of directors includes executive directors Zhang Xiaolong and Wei Liang, along with independent non-executive directors [9].

Financial Performance - For Q3 2025, Autohome Inc. reported total net revenue of RMB 1,778.1 million (USD 249.8 million), a slight increase from RMB 1,774.5 million in Q3 2024[9]. - The net profit attributable to Autohome Inc. for Q3 2025 was RMB 436.6 million (USD 61.3 million), compared to RMB 441.3 million in the same period last year, reflecting a decrease of 1.5%[18]. - Adjusted net profit (non-GAAP) for Q3 2025 was RMB 406.9 million (USD 57.2 million), down from RMB 497.2 million in Q3 2024[9]. - Operating profit for Q3 2025 was RMB 147.0 million (USD 20.7 million), an increase from RMB 82.6 million in Q3 2024[16]. - In Q3 2025, net profit attributable to ordinary shareholders was RMB 419.4 million (USD 58.9 million), slightly down from RMB 425.7 million in Q3 2024[19]. - Basic and diluted earnings per share for Q3 2025 were RMB 0.89 (USD 0.13), compared to RMB 0.88 and RMB 0.87 in Q3 2024[19]. - Adjusted basic and diluted earnings per share for Q3 2025 were RMB 0.87 (USD 0.12) and RMB 0.86 (USD 0.12), respectively, compared to RMB 1.02 in Q3 2024[20]. Revenue and Growth - Daily active users on mobile platforms reached 76.56 million in September 2025, representing a year-over-year growth of 5.1%[10]. - Online marketing and other business revenues grew by 32.1% year-over-year in Q3 2025, driven by strong contributions from the new retail business[10]. Expenses and Costs - Operating costs for Q3 2025 were RMB 646.0 million (USD 90.7 million), significantly higher than RMB 407.7 million in Q3 2024, primarily due to increased transaction costs from expanding into lower-tier markets[12]. - Research and development expenses for Q3 2025 were RMB 278.6 million (USD 39.1 million), down from RMB 339.2 million in the same quarter last year, mainly due to reduced personnel-related costs[15]. Dividends and Share Repurchase - The company approved a cash dividend of USD 1.20 per American depositary share, totaling approximately RMB 1 billion, with total declared cash dividends for 2025 reaching RMB 1.5 billion[9]. - The company has repurchased 5,483,238 American depositary shares for a total amount of approximately USD 145.9 million as of October 31, 2025[9]. Cash Flow and Assets - As of September 30, 2025, cash and cash equivalents totaled RMB 21.89 billion (USD 3.08 billion) with net cash flow from operating activities at RMB 66.6 million (USD 9.4 million)[21]. - Total assets increased to RMB 30,221,625 as of December 31, 2024, up from RMB 28,773,351 as of September 30, 2024, representing a growth of 5.0%[37]. - Cash and cash equivalents decreased to RMB 1,693,597 from RMB 3,012,339, a decline of 43.7%[37]. - Short-term investments rose to RMB 21,621,992, an increase of 14.6% compared to RMB 18,880,945 in the previous quarter[37]. - Total current assets reached RMB 25,163,851, an increase of 6.2% from RMB 23,690,755[37]. Liabilities and Equity - Total liabilities increased to RMB 5,020,975, up 45.3% from RMB 3,451,212[37]. - Current liabilities surged to RMB 4,529,794, a significant increase of 53.0% from RMB 2,959,042[37]. - Total equity stood at RMB 23,269,121, slightly up from RMB 23,249,006, indicating a marginal growth of 0.09%[37]. Future Outlook and Strategy - The company aims to leverage technology to reduce decision-making and transaction costs in the automotive industry[26]. - The company utilizes non-GAAP financial metrics to provide a clearer picture of its financial performance, excluding certain expenses[28]. Employee and Conference Information - Total employees as of September 30, 2025, numbered 4,259, including 1,206 from Tian Tian Pai Che[23]. - The earnings conference call is scheduled for November 6, 2025, at 7:00 AM ET[24].

Financial Performance - Total revenue for Q3 2025 reached $1.41 billion, a year-on-year increase of 41%[6] - Global revenue for Baiyueze® (Zebutinib) in Q3 2025 was $1 billion, reflecting a 51% year-on-year growth[6] - GAAP diluted earnings per ADS for Q3 2025 were $1.09, compared to a loss of $1.15 in Q3 2024, marking a 195% improvement[7] - Adjusted diluted earnings per ADS for Q3 2025 were $2.65, up 452% from $0.48 in Q3 2024[7] - Operating profit (loss) under GAAP for Q3 2025 was $163.11 million, a 236% increase from a loss of $120.27 million in Q3 2024[7] - Adjusted operating profit (loss) for Q3 2025 was $341.18 million, a 420% increase from $65.63 million in Q3 2024[7] - Free cash flow for Q3 2025 was $354.47 million, a significant increase of 548% from $54.71 million in Q3 2024[7] - GAAP net profit for Q3 2025 was $125 million, an increase of $246 million compared to a loss in the same period last year[14] - Total revenue for the nine months ended September 30, 2025, reached $3,844,863, compared to $2,682,417 for the same period in 2024, marking an increase of about 43.2%[32] - Net profit for the three months ended September 30, 2025, was $124,841, a significant improvement from a net loss of $121,350 in the same period of 2024[32] Revenue Breakdown - Product revenue for Q3 2025 reached $1.4 billion, compared to $993 million in Q3 2024, driven primarily by increased sales of Baiyueze®[8] - Baiyueze® sales in the U.S. for Q3 2025 were $739 million, a 47% increase year-over-year, driven by strong demand across all indications[11] - Baizean® sales for Q3 2025 were $191 million, representing a 17% year-over-year increase, supported by ongoing clinical advancements[11] Expenses and Costs - R&D expenses for Q3 2025 were $523.7 million, a 6% increase from $496.2 million in Q3 2024, reflecting ongoing clinical project advancements[10] - SG&A expenses for Q3 2025 totaled $529 million, a 16% increase from $455.2 million in Q3 2024, driven by global commercialization efforts[10] - Operating expenses for the three months ended September 30, 2025, totaled $1,052,660, compared to $951,402 in the same period of 2024, indicating an increase of about 10.7%[32] - Adjusted operating expenses for the nine months ended September 30, 2025, were $2,582,806, compared to $2,310,299 in the same period of 2024, representing an increase of 11.8%[39] Guidance and Future Plans - The company has updated its financial guidance for the fiscal year 2025 based on current information available[2] - The company updated its full-year 2025 revenue guidance to between $5.1 billion and $5.3 billion, reflecting strong growth expectations for Baiyueze®[15] - The company plans to continue advancing its late-stage hematological oncology pipeline, including promising candidates like Sotokura and BGB-16673[6] - The company expects to obtain orphan drug designation for Baiyueze® for marginal zone lymphoma (MZL) in Japan by the first half of 2026[23] - The company plans to initiate a Phase 3 trial for BGB-43395 (CDK4 inhibitor) in HR-positive, HER2-negative metastatic breast cancer in the first half of 2026[23] Market Presence - Baiyueze® is currently approved in 75 markets globally, with reimbursement in 57 markets, indicating significant market penetration[17] - 47 abstracts were accepted for presentation at the American Society of Hematology (ASH) annual meeting[6] Cash Flow and Assets - Cash and cash equivalents as of September 30, 2025, were $4,110,542, an increase from $2,638,747 as of December 31, 2024[34] - Total assets as of September 30, 2025, amounted to $7,632,586, compared to $5,920,910 as of December 31, 2024, representing an increase of approximately 29.0%[34] - The company reported a net cash provided by operating activities of $402,553 for the three months ended September 30, 2025, compared to $188,369 in the same period of 2024[36] Legal and Regulatory - The company announced that Pharmacyclics will not appeal the final written decision regarding the invalidation of the U.S. patent related to Baiyueze®[28] - The company has reached an agreement with Royalty Pharma to sell rights to receive royalties on global sales of Tarlatamab outside of China, with a potential transaction value of up to $950 million[28] Earnings Call - The third quarter earnings conference call is scheduled for November 6, 2025, at 8 AM ET, with a live stream available on the company's investor page[26]

Financial Performance - The group reported a net loss of approximately RMB 8.6 million for the six months ended June 30, 2025, with no revenue generated during this period [3]. - Revenue for the six months ended June 30, 2025, was approximately RMB 86.4 million, an increase from RMB 54.9 million in the same period of 2024 [6]. - The sales and distribution costs as a percentage of revenue decreased from approximately 6.8% for the six months ended June 30, 2024, to about 4.5% for the same period in 2025 [6]. - General and administrative expenses as a percentage of revenue decreased from approximately 19.5% for the six months ended June 30, 2024, to about 16.2% for the same period in 2025 [6]. Liabilities and Financing - Current liabilities and total liabilities were approximately RMB 273.6 million as of June 30, 2025, including bank loans and accrued interest totaling about RMB 193.5 million [3]. - The company issued two five-year bonds of HKD 5 million each in February and June 2025, with an annual interest rate of 5% to raise funds for operational activities [4]. - As of the announcement date, the company has not completed any new debt financing [5]. Shareholder Engagement - The company is actively seeking shareholder support for a share consolidation and change in trading unit to address low share price issues and enhance future fundraising flexibility [4]. - The company plans to issue quarterly updates to inform shareholders and investors of any significant developments [7].